natgillin/translations-raw huggingface dataset:
The compound, or pharmaceutically acceptable salt thereof, of claim 64 for use in treating cancer wherein said cancer is bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, cancer of the kidney, liver cancer, lung cancer, nasopharygeal cancer, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, Kaposi's sarcoma, multiple myeloma, lymphoma, adult T cell leukemia, acute myelogenous leukemia, chronic myeloid leukemia. glioblastoma, astrocytoma, melanoma, mesothelioma, or Wilm's tumor. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 64, naznačeni time da se upotrebljavaju u liječenju raka pri čemu je navedeni rak rak mokraćnog mjehura, rak dojke, rak grlića materice, kolangiokarcinom, rak debelog crijeva, rak jednjaka, rak želuca, rak glave i vrata, rak bubrega, rak jetre, rak pluća, nazofaringealni rak, rak jajnika, rak pankreasa, rak prostate, rak štitne žlijezde, osteosarkom, sinovijalni sarkom, rabdomiosarkom, MFH/fibrosarkom, leiomiosarkom, Kaposijev sarkom, multipli mijelom, limfom, leukemija odraslih T stanica, akutna mijelogena leukemija, kronična mijeloična leukemija, glioblastom, astrocitom, melanom, mezoteliom ili Wilmsov tumor.
mixing the composition obtained in step (a) with a lubricant; and 
miješanja s lubrikantom sastava dobivenog u koraku (a); i
optionally compressing the composition obtained in step (b). 
opcijski stlačivanja sastava dobivenog u koraku (b).
Process for the manufacture of a pharmaceutical composition comprising 0.01 mg to 0.9 mg of aleglitazar or a salt thereof comprising: 
Postupak za proizvodnju farmaceutskog sastava, koji sadrži 0,01 mg do 0,9 mg aleglitazara ili njegove soli, naznačen time, da obuhvaća:
mixing the composition obtained in step (a) with a lubricant; and 
miješanje s lubrikantom sastava dobivenog u koraku (a); i
optionally compressing the composition obtained in step (b). 
opcijski stlačivanje sastava dobivenog u koraku (b).
Pharmaceutical composition or process according to claim 1 or 2, wherein the solution of step (a) is an aqueous solution. 
Farmaceutski sastav ili postupak prema zahtjevu 1 ili 2, naznačen time, da otopina iz koraka (a) je vodena otopina.
Pharmaceutical composition or process according to claim 6, wherein the binder is povidone. 
Farmaceutski sastav ili postupak prema zahtjevu 6, naznačen time, da vezivo je povidon.
Pharmaceutical composition or process according to claim 8, wherein the surfactant is sodium lauryl sulfate. 
Farmaceutski sastav ili postupak prema zahtjevu 8, naznačen time, da tenzid je natrijev lauril sulfat.
Pharmaceutical composition or process according to claim 10, wherein the disintegrant is croscarmellose sodium. 
Farmaceutski sastav ili postupak prema zahtjevu 10, naznačen time, da dezintegrator je kroskarmeloza-natrij.
Pharmaceutical composition or process according to claim 12, wherein the lubricant is magnesium stearate. 
Farmaceutski sastav ili postupak prema zahtjevu 12, naznačen time, da lubrikant je magnezijev stearat.
Magnesium stearate 3 mg. Pharmaceutical composition according to any one of claims 1 or 3 to 15 in the form of a tablet. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 ili 3 do 15, naznačen time, da je u obliku tablete.
Pharmaceutical composition according to any one of claims 1 or 3 to 16 for use as medicament for the treatment or prophylaxis of diabetes type II or cardiovascular diseases. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 ili 3 do 16, naznačen time, da se upotrebljava kao lijek za liječenje ili profilaksu dijabetesa tipa II ili kardiovaskularnih bolesti.
An extract of Cissampelos pareira for use in the treatment of dengue virus infection according to claim 1, which is prepared by a process comprising: 
Ekstrakt Cissampelos pareira za uporabu u liječenju od denga virusom prema zahtjevu 1, naznačen time, da se priprema postupkom koji obuhvaća:
partitioning the mixture obtained in step (d). 
odvajanje smjese dobivene u koraku (d).
An extract for use according to claim 5, 6 or 7, wherein the alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and mixtures thereof, the ketone is selected from the group consisting of acetone, methyl isobutyl ketone and mixtures thereof, the ester is selected from the group consisting of methyl acetate, ethyl acetate and mixtures thereof, the halogenated hydrocarbon is selected from the group consisting of chloroform, dichloromethane, ethylene dichloride and mixtures thereof, the ether is diethyl ether and the petroleum fraction is selected from the group consisting of hexane, petroleum ether, heptane and mixtures thereof. 
Ekstrakt za uporabu u skladu s patentnim zahtjevom 5, 6 ili 7, naznačen time, da je alkohol odabran iz skupine koju čine metanol, etanol, propanol, izopropanol, butanol i njihove smjese, keton je odabran iz skupine koju čine aceton, metil izobutil keton i njihove mješavine, ester je odabran iz skupine koju čine metil acetat, etil acetat i njihove smjese, halogenirani ugljikovodik je odabran iz skupine koju čine kloroform, diklorometan, etilen diklorida i njihovih smjesa, eter je dietil eter i naftna frakcija je odabrana iz skupine koja se sastoji od heksana, petroletera, heptana i njihovih smjese.
Device, according to one or more of the previous claims, characterised in that the flashing of the indicator light of the receiver (4) is synchronised with that of the transmitter (3), by sending a sequence of infrared pulses, with at least two transmission frequencies. 
Mehanizam prema jednom ili više od prethodnih zahtjeva, naznačen time da se bljeskanje dojavnog svjetla prijemnika (4) sinkronizira s onim odašiljača (3) tako što se s najmanje dvije prijenosne frekvencije odašilje niz infracrvenih impulsa.
Cinacalcet intermediate having the following formula (V) 
Intermedijer sinakalceta sa sljedećom formulom (V) [image]
Cinacalcet intermediate having the following formula (Vb) wherein Bn is benzyl. 
Intermedijer sinakalceta sa sljedećom formulom (Vb) [image] gdje je Bn benzil.
A process for the preparation of Cinacalcet intermediate of formula (V) as defined in claim 1, comprising the step of: 
Postupak pripreme intermedijera sinakalceta formule (V) kako je definirano u zahtjevu 1, koji obuhvaća korak:
A process for the preparation of Cinacalcet intermediate of formula (V) as defined in claim 1, comprising the steps of: 
Postupak pripreme intermedijera sinakalceta formule (V) kako je definirano u zahtjevu 1, koji obuhvaća korake:
with a compound of formula HNR1R2 wherein R1 and R2 represent, independently, hydrogen or C1-C5 alkyl, provided that when one of R1 and R2 is hydrogen, the other is not hydrogen; or wherein R1 and R2 together form a C4-C7-alkylene bridge, so that with the inclusion of the nitrogen atom to which they are linked form a heterocycle, wherein one -CH2- group of the C4-C7-alkylene bridge, can be replaced by - O-, in the presence of formaldehyde; or 
sa spojem formule HNR1R2 gdje R1 i R2 predstavljaju, nezavisno, vodik ili C1-C5 alkil, uz uvjet da kada je jedan od R1 i R2 vodik, drugi nije vodik; ili gdje R1 i R2 zajedno formiraju C4-C7-alkilenski most, tako da s umetanjem atoma dušika s kojim su spojeni formiraju heterocikl, gdje jedna -CH2- skupina u C4-C7-alkilenskom mostu, može biti zamijenjena s - O-, u prisutnosti formaldehida; ili
with a N-methyl-N-methylenemethanaminium halide of formula wherein Hal is a halogen atom, to give the compound of formula (IV) wherein R1 and R2 at defined above; 
s N-metil-N-metilenmetanaminijevim halidom formule [image] gdje Hal je atom halogena, da se dobije spoj formule (IV) [image] gdje su R1 i R2 kako je gore definirano;
alkylating the compound of formula (IV) with an alkylating agent selected from the group of compounds of formula: 
alkiliranje spoja formule (IV) sa sredstvom za alikiliranje izabranim iz grupe spojeva formule:
A process for preparing Cinacalcet of formula (I) comprising preparing Cinacalcet intermediate of formula (V) according to claim 4 or 5, and converting it to Cinacalcet of formula (I). 
Postupak pripreme sinakalceta formule (I) [image] koji obuhvaća pripremu intermedijera sinakalceta formule (V) prema zahtjevu 4 ili 5, i njegovu pretvorbu u sinakalcet formule (I).
A process for the preparation of Cinacalcet intermediate of formula (Va) as defined in claim 2, which comprises the step of: 
Postupak pripreme intermedijera sinakalceta formule (Va) kako je definirano u zahtjevu 2, koji obuhvaća korak:
reducing the compound of formula (V) as defined in claim 1, in the presence of a reducing agent or by mean of a catalytic hydrogenation process, to give the compound of formula (Va). 
redukcija spoja formule (V) kako je definirano u zahtjevu 1, u prisutnosti reducensa ili pomoću procesa katalitičke hidrogenacije, da se dobije spoj formule (Va).
A process for preparing Cinacalcet intermediate of formula (Va) according to claim 7, comprising preparing the compound of formula (V) according to claim 4 or 5. 
Postupak pripreme intermedijera sinakalceta formule (Va) prema zahtjevu 7, koji obuhvaća pripremu spoja formule (V) prema zahtjevu 4 ili 5.
A process for preparing Cinacalcet of formula (I) comprising preparing Cinacalcet intermediate of formula (Va) according to claim 7 or 8, and converting it to Cinacalcet of formula (I). 
Postupak pripreme sinakalceta formule (I) [image] koji obuhvaća pripremu intermedijera sinakalceta formule (Va) prema zahtjevu 7 ili 8, i njegovu pretvorbu u sinakalcet formule (I).
reducing the compound of formula (V) as defined in claim 1, with Zn, in the presence of an acid, so obtaining the compound of formula (VI), in a mixture with Cinacalcet of formula (I). 
redukcija spoja formule (V) kako je definirano u zahtjevu 1, sa Zn, u prisutnosti kiseline, da se tako dobije spoj formule (VI), u smjesi sa sinakalcetom formule (I).
A process for preparing Cinacalcet intermediate of formula (VI) according to claim 10, comprising preparing the compound of formula (Va) according to claim 7 or 8. 
Postupak pripreme intermedijera sinakalceta formule (VI) prema zahtjevu 10, koji obuhvaća pripremu spoja formule (Va) prema zahtjevu 7 ili 8.
A process for preparing Cinacalcet intermediate of formula (VI) according to claim 10, comprising preparing the compound of formula (V) according to claim 4 or 5. 
Postupak pripreme intermedijera sinakalceta formule (VI) prema zahtjevu 10, koji obuhvaća pripremu spoja formule (V) prema zahtjevu 4 ili 5.
reducing the compound of formula (V) in the presence of a reducing agent or by mean of a catalytic hydrogenation process to give a compound of formula (Va) 
redukcija spoja formule (V) u prisutnosti reducensa ili pomoću procesa katalitičke hidrogenacije da se dobije spoj formule (Va) [image]
dehydrating a compound of formula (Va) with a dehydrating agent to give a compound of formula (VI) 
dehidracija spoja formule (Va) sa sredstvom za dehidraciju da se dobije spoj formule (VI) [image]
reducing the compound of formula (VI), to give Cinacalcet of formula (I) and, if desired, converting Cinacalcet into a pharmaceutically acceptable salt. 
redukcija spoja formule (VI), da se dobije sinakalcet formule (I) i, po želji, pretvorba sinakalceta u farmaceutski prihvatljivu sol.
reducing the compound of formula (V) as defined above with Zn, in the presence of an acid, so obtaining the compound of formula (VI) in admixture with Cinacalcet of formula (I); 
redukcija spoja formule (V) kako je gore definirano sa Zn, u prisutnosti kiseline, da se tako dobije spoj formule (VI) [image] u zajedničkoj smjesi sa sinakalcetom formule (I);
reacting the compound of formula (II) 
reakcija spoja formule (II) [image]
with a compound of formula HNR1R2, wherein R1 and R2 represent, independently, hydrogen or C1-C5 alkyl, provided that when one of R1 and R2 is hydrogen, the other is not hydrogen; or wherein R1 and R2 together form a C4-C7-alkylene bridge, so that with the inclusion of the nitrogen atom to which they are linked a heterocycle is formed, wherein one -CH2- group of the C4-C7-alkylene bridge, can be replaced by -O-, in the presence of formaldehyde; or 
sa spojem formule HNR1R2, gdje R1 i R2 predstavljaju, nezavisno, vodik ili C1-C5 alkil, uz uvjet da kada je jedan od R1 i R2 vodik, drugi nije vodik; ili gdje R1 i R2 zajedno formiraju C4-C7-alkilenski most, tako da s umetanjem atoma dušika s kojim su spojeni nastane heterocikl, gdje jedna -CH2- skupina u C4-C7-alkilenskom mostu, može biti zamijenjena s -O-, u prisutnosti formaldehida; ili
with a N-methyl-N-methylenemethanaminium halide of formula wherein Hal is a halogen atom, to give the compound of formula (IV) wherein R1 and R2 are as defined above; 
s N-metil-N-metilenmetanaminijevim halidom formule [image] gdje Hal je atom halogena, da se dobije spoj formule (IV) [image] gdje su R1 i R2 kako je gore definirano;
reacting the compound of formula (II) as defined above 
reakcija spoja formule (II) kako je gore definirano
with a N-methyl-N-methylenemethanaminium halide of formula wherein Hal is a halogen atom, to obtain the compound of formula (IV) wherein R1 and R2 are as defined above; 
s N-metil-N-metilenmetanaminijevim halidom formule [image] gdje Hal je atom halogena, da se dobije spoj formule (IV) [image] gdje su R1 i R2 kako je gore definirano;
reducing the double bond of the compound of formula (VI), to give Cinacalcet of formula (I) and, if desired, converting Cinacalcet into a pharmaceutically acceptable salt. 
redukcija dvostruke veze u spoju formule (VI), da se dobije sinakalcet formule (I) i, po želji, pretvorba sinakalceta u farmaceutski prihvatljivu sol.
A compound according to claim 1, wherein A represents wherein the asterisks indicate the bond that is linked to the pyridine group of Formula (I); and a salt of such a compound. 
Spoj prema zahtjevu 1, naznačen time, da A predstavlja [image] gdje zvjezdice označavaju vezu koja je spojena na piridin-skupinu formule (I); i sol takvog spoja.
Compounds according to claim 1 or 2, characterised in that represents H; methyl; ethyl; n-propyl; or isopropyl; 
Spojevi prema zahtjevu 1 ili 2, naznačeni time da R4 predstavlja H; metil; etil; n-propil; ili izopropil;
R5a represents H or CH3, preferably H, if A represents N; 
a predstavlja H ili CH3, poželjno H, ako A predstavlja N;
o represents 0 or 1, 
o predstavlja 0 ili 1,
or (a2) represents one of the substructures (T3c) or (T3d) in which W represents N or CR9; 
ili (a2) predstavlja jednu od podstruktura (T3c) ili (T3d) [image] gdje W predstavlja N ili CR9;
or (a3) represents one of the substructures (T3e) or (T3f) in which W represents N or CR9; 
ili (a3) predstavlja jednu od podstruktura (T3e) ili (T3f) [image] gdje W predstavlja N ili CR9;
or (a5) represents one of the substructures (T3i) or (T3j) in which W represents N or CR9; 
ili (a5) predstavlja jednu od podstruktura (T3i) ili (T3j) [image] gdje W predstavlja N ili CR9;
R5a represents H if A represents N; or represents H; methyl; ethyl; n-propyl; isopropyl if A represents CR5b; 
a predstavlja H ako A predstavlja N; ili predstavlja H; metil; etil; n-propil; izopropil ako A predstavlja CR5b;
U represents CR7; 
U predstavlja CR7;
Pharmaceutical composition containing at least one compound according to any one of the preceding claims, in the form of an individual stereoisomer or the mixture thereof, the free compounds and/or their physiologically compatible salts, and also if appropriate suitable additives and/or auxiliaries and/or if appropriate further active ingredients. 
Farmaceutski pripravak naznačen time da sadrži barem jedan spoj prema bilo kojem od prethodnih zahtjeva, u obliku pojedinačnog stereoizomera ili njihove smjese, slobodnih spojeva i/ili njihovih fiziološki kompatibilnih soli, te također ako je prikladno pogodne aditive i/ili pomoćne tvari i/ili ako je prikladno dodatne aktivne sastojke.
The crystalline salt form of Claim 8, wherein the crystalline salt form is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in Figure 5. 
Kristalni oblik soli u skladu s patentnim zahtjevom 8, naznačen time, da je kristalni oblik soli karakteriziran bilježenjem traga diferencijalnom pretražnom kalorimetrijom u bitnome u skladu s onom prikazanom na Slici 5.
isolating the crystalline sulfate salt from the second reaction mixture; or 
izoliranja kristalne sulfatne soli iz druge reakcijske smjese; ili
isolating the crystalline sulfate salt from the reaction mixture; or 
izoliranja reakcijske smjese kristalnog oblika sulfatne; ili
isolating the crystalline sulfate salt from the reaction mixture. 
izoliranja kristalne sulfatne soli iz reakcijske smjese.
a pilot inserter (404) for inserting pilot signals to the signal frame; a modulator (104) configured to Modulate the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and 
modulator (104) konfiguriran za moduliranje izgrađenog okvira signala pomoću metode ortogonalnog umnožavanja dijeljenja frekvencije, OFDM; i jedinicu za prijenos konfiguriranu za prijenos moduliranog okvira signala.
a demodulator (r104) configured to demodulate a signal carrying a signal frame by use of an Orthogonal Frequency Division Multiplexing,OFDM, method; 
demodulator (r104) konfiguriran za demoduliranje primljenog signala pomoću metode ortogonalnog umnožavanja dijeljenja frekvencije, OFDM;
obtaining the signal frame, from which the pilot signals are deleted, from the demodulated signal, the signal frame comprising preamble symbols and at least one data slice, the data slice including Physical Layer Pipe, PLP, data symbols of one or more PLPs, wherein the preamble symbols have Layer 1, L1, signaling information for signaling the data slice; 
dobivanje okvira signala iz demoduliranih signala, okvir signala obuhvaća signale početnih nizova i najmanje jedan podatkovni rez, podatkovni rez uključuje simbole podataka cijevi fizičke razine, PLP, pri čemu simboli početnih nizova imaju informaciju signaliziranja razine 1, L1, za signaliziranje podatkovnog reza i podatkovni rez uključuje jedan ili više PLP podataka;
A method for assessing renal toxicity in an individual following administration of compound suspected of causing renal toxicity, wherein the renal toxicity is identified by measurement of a set of biomarkers in a urine sample from the individual and comparison of the measured biomarker amount with the corresponding amount in a healthy individual, wherein the biomarkers are selected from the group consisting of the biomarkers listed in TABLE 1 and include cystatin C protein, and wherein the renal toxicity is glomerular alterations / damage. 
Postupak za procjenu bubrežne toksičnosti kod pojedinca nakon davanja spoja za koji se sumnja da izaziva bubrežnu toksičnost, naznačen time da se bubrežna toksičnost utvrđuje mjerenjem skupa biomarkera u uzorku urina pojedinca, te se provodi usporedba iznosa izmjerenih biomarkera s odgovarajućim iznosom kod zdravog pojedinca, pri čemu su biomarkeri su odabrani iz skupine koja se sastoji od biomarkera navedenih u tablici 1, a uključuju 2-mikroglobulinski protein, te gdje renalna toksičnost su glomerulske promjene ili oštećenja.
The forming method according to claim 7, characterized in that it comprises the step of detachably separating at least two parts of the formed container. 
Postupak oblikovanja prema zahtjevu 7, naznačen time, da obuhvaća korak odvojivog rastavljanja spomenutih najmanje dva dijela oblikovanog spremnika.
The forming method according to claim 8, characterized in that said separationing step consists in detaching said two lateral containment elements (4) from lateral protrusions (7) which are connected to mutually opposite edges of said base (2). 
Postupak oblikovanja prema zahtjevu 8, naznačen time, da se spomenuti korak rastavljanja sastoji od odvajanja spomenutih dva bočna priključna elementa (4) od spomenutih bočnih izbočina (7), koji su spojeni na međusobno nasuprotne rubove spomenute baze (2).
An antibody or antigen-binding fragment of an antibody according to any one of claims 1 to 5 for use in the attenuation or inhibition of an IL-6 mediated disease or disorder in a human, where the IL-6-mediated disease or disorder is arthritis, an inflammatory bowel disease or systemic lupus erythematosus. 
Antitijelo ili njegov fragment koji se veže na antigen prema bilo kojem od patentnih zahtjeva 1 - 5, naznačen time, da se upotrebljava za ublažavanje ili inhibiciju bolesti ili poremećaja u čovjeka kojima je IL-6 medijator pri čemu su bolest ili poremećaj kojima je IL-6 medijator artritis, upalna bolest crijeva ili sistemski eritematozni lupus.
The oral formulation according to anyone of claims 1 to 5 characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of inecalcitol. 
Oralna formulacija prema bilo kojem patentnom zahtjevu od 1 do 5, naznačena time da ima poboljšani apsorpcijski profil u odnosu na formulaciju inekalcitola sa srednjolančanim trigliceridima (MCT).
Method for searching multimedia contents in the Internet, comprising the steps of: 
Metoda pretraživanja multimedijalnih sadržaja na internetu koja sadrži sljedeće korake:
connecting a client (1) to the Internet, 
spajanje korisnika (1) na internet
transmitting the search text (xxx) from the client (1) to the Internet provider (3), 
prenošenje teksta pretrage (xxx) s korisnika (1) na pružatelja internetskih usluga (3),
transmitting a results page (20a) from the Internet provider (3) to the client (1), including at least an Internet address for each multimedia contents detected (R1,..., RN), characterized by comprising the following steps: 
prenošenje stranice s rezultatima (20a) s pružatelja internetskih usluga (3) na korisnika (1) koja uključuje najmanje jednu internetsku adresu za svaki pronađeni multimedijalni sadržaj (R1,..., RN), naznačena time da sadrži sljedeće korake:
defining predetermined types (T1,..., TN) of multimedia contents, 
definiranje predodređenih vrsta (T1, TN) multimedijalnih sadržaja,
automatically associating each multimedia contents detected (R1,..., RN) to a predetermined type (T1,..., TN), 
automatsko povezivanje svakog pronađenog multimedijalnog sadržaja (R1, RN) s predodređenom vrstom (T1,..., TN),
dividing the results page (20a) in a plurality of areas (A1,..., An), each associated to a corresponding type (T1,..., TN), 
podjela stranice s rezultatima (20a) na mnoštvo odjeljaka (A1, An), svaki povezan s odgovarajućom vrstom (T1, TN)
Method according to claim 1 characterized by the fact that said step of defining said types (T1,..., TN) includes a step of setting at least a displaying program or a player to each type (T1,..., TN), for displaying said multimedia contents. 
Metoda prema patentnom zahtjevu 1, naznačena time da navedeni korak definiranja navedenih vrsta (T1,..., TN) uključuje korak podešavanja najmanje jednog programa za prikazivanje ili preglednika za svaku vrstu (T1,..., TN) radi prikazivanja navedenih multimedijalnih sadržaja.
Method according to claim 1 characterized by the fact that said step of loading said Internet addresses includes a step of transmitting said multimedia contents (R1,..., RN) from said server (50-54) to a memory of said client (1). 
Metoda prema patentnom zahtjevu 1, naznačena time da navedeni korak učitavanja navedenih internetskih adresa uključuje korak prenošenja navedenih multimedijalnih sadržaja (R1,..., RN) s navedenog poslužitelja (50-54) u memoriju navedenog korisnika (1).
Method according to claim 4 characterized by the fact that said step of selecting said multimedia content (R1,..., RN) comprises a step of transmitting the multimedia content selected (R1,..., RN) from the server (50-54) to the memory of the client (1). 
Metoda prema patentnom zahtjevu 4, naznačena time da navedeni korak odabira navedenog multimedijalnog sadržaja (R1,..., RN) sadrži korak prenošenja odabranog multimedijalnog sadržaja (R1,..., RN) s poslužitelja (50-54) u memoriju korisnika (1).